Sennur Gorgulu

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that supports the findings of this study is available in of this article. Supporting Information Filename Description cbdd70322-sup-0001-TableS1-FigureS1-S25.docxWord 2007 document , 4.7 MB Table S1: SwissADME analyses of compounds 6e, 6g, 6k, 6l. Figure S1: 1H NMR spectrum of compound 6a. Figure S2: 13C NMR spectrum of compound 6a. Figure S3: Mass spectra of compound 6a.

A., H. E.Bostancı, Ş.Görgülü, M. T.Yıldız, and U.Acar Çevik. 2026. “Design and Synthesis of New Triazol Derivatives as Aromatase Enzyme Inhibitors.” Chemical Biology & Drug Design107, no. 3: e70276. Çelik, https://doi.org/10.1111/cbdd.70276. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The authors have nothing to report.

1 INTRODUCTION Cancer, one of the most serious diseases to threaten human life, is characterized as a rebound system of uncontrolled cellular growth (Alotaibi et al., 2023; Saleh et al., 2023). Treatment options for cancer include surgery, radiation therapy, and chemotherapy (Khaled et al., 2023). An ongoing problem for cancer researchers is to develop tailored chemotherapy drugs that can interact with cancer cells' molecular targets in a way that inhibits their growth.